{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T08:46:24Z","timestamp":1698050784730},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":6688,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1991,1]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> The treatment of relapsing or refractory high\u2010grade malignant non\u2010Hodgkin lymphoma (NHL) following CHOP chemotherapy remains a challenge for the clinician. In this study, 29 patients with relapsing or refractory high\u2010 or refractory low\u2010grade malignant NHL received a combination of mitoxantrone 12 mg\/m<jats:sup>2<\/jats:sup> i.v. on days 1\u20132, cytarabine 100 mg\/m<jats:sup>2<\/jats:sup> i.v., b.d. d 1\u20132, etoposide 100 mg\/m<jats:sup>2<\/jats:sup> i.v. d 1\u20133 and prednisone 100 mg\/m<jats:sup>2<\/jats:sup> orally d 1\u20133 (ENAP). An overall response rate of 55% encouraged us to use ENAP alternated with conventional CHOP chemotherapy in 45 previously untreated NHL patients (35 with high\u2010grade and 10 with \u201caggressive\u201d low\u2010grade malignant NHL). All patients responded with a complete remission rate (CR) of (27%) and a partial remission rate (PR) of 73% after only one course of ENAP. After a median number of 3.5 ENAP\/CHOP courses, the CR and PR rate was 69 and 22%, respectively. Myelo\u2010suppression was pronounced and fever of unidentified origin and documented infections followed 59% of all cases given ENAP courses. In the last 19 previously untreated patients mitoxantrone was given at a dose of 10 mg\/m<jats:sup>2<\/jats:sup> on d 1 and cytarabine 100 mg i.v., b.d. during d 1\u20132. Non\u2010hematologic toxicity was mild. We conclude that this novel chemotherapy program is effective both as first\u2010line and salvage treatment in patients with high\u2010grade malignant NHL. Furthermore, ENAP appears clinically to be partly non\u2010cross resistant with CHOP chemotherapy. The dose\u2010limiting toxicity is myelosuppression. The combination should be explored as primary therapy in combination with other chemotherapy or radiotherapy programs.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1991.tb00510.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T02:43:33Z","timestamp":1279421013000},"page":"33-37","source":"Crossref","is-referenced-by-count":4,"title":["Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non\u2010Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL"],"prefix":"10.1111","volume":"46","author":[{"given":"Karl","family":"Merk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kajsa","family":"Idestr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Lindemalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"\u00d6sby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91142-3"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.10.1318"},{"issue":"9","key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.1985.3.9.1188","article-title":"Phase II study of BCOP v CHOP in unfavourable categories of malignant lymphoma: A Southeastern Cancer Study Group trial","volume":"3","author":"Gams RA","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.2.91"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90522-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-102-5-596"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-3-304"},{"issue":"1","key":"e_1_2_1_9_2","first-page":"50","article-title":"Mitoxantrone in refractory non\u2010Hodgkin's lymphoma: A Southwest Oncology Group Study","volume":"11","author":"Coltman CA","year":"1984","journal-title":"Semin Oncol"},{"issue":"1","key":"e_1_2_1_10_2","first-page":"47","article-title":"Mitoxantrone in malignant lymphoma","volume":"11","author":"Gams RA","year":"1984","journal-title":"Semin Oncol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891001)64:7<1388::AID-CNCR2820640703>3.0.CO;2-0"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174161"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.2.213"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254243"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850901)56:5<1006::AID-CNCR2820560505>3.0.CO;2-7"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198204013061303"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-81092-3"},{"key":"e_1_2_1_18_2","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.407"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02579920"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198908000-00010"},{"key":"e_1_2_1_22_2","unstructured":"HagbergH. LindemalmC. Cavallin\u2010St\u00e4hlE.et al.(For the Swedish Lymphoma Study Group).CHOP vs CHOP\u2010M in the treatment of high grade malignant non\u2010Hodgkin lymphomas in adults. (Abstract: Lugano Lymphoma Conference 1987)."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(85)90169-5"},{"key":"e_1_2_1_24_2","first-page":"227","article-title":"Marrow transplantation for malignant lymphoma","volume":"2","author":"Appelbaum FR.","year":"1987","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.9.1340"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162402"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162401"},{"key":"e_1_2_1_28_2","first-page":"7","article-title":"Treatment of poor prognosis non\u2010Hodgkin's lymphoma using cyclophosphamide and total body irradiation regimens with autologous bone marrow rescue","volume":"2","author":"Braine HG","year":"1987","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1554"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1991.tb00510.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1991.tb00510.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:43:46Z","timestamp":1698018226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1991.tb00510.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1991,1]]}},"alternative-id":["10.1111\/j.1600-0609.1991.tb00510.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1991.tb00510.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,1]]}}}